Synthesis, QSAR studies, and metabolic stability of novel 2-alkylthio-4-chloro-N-(5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives as potential anticancer and apoptosis-inducing agents

被引:9
作者
Zolnowska, Beata [1 ]
Slawinski, Jaroslaw [1 ]
Pogorzelska, Aneta [1 ]
Szafranski, Krzysztof [1 ]
Kawiak, Anna [2 ,3 ,4 ]
Stasilojc, Grzegorz [5 ]
Belka, Mariusz [6 ]
Zielinska, Joanna [6 ]
Baczek, Tomasz [6 ]
机构
[1] Med Univ Gdansk, Dept Organ Chem, Gdansk, Poland
[2] Univ Gdansk, Dept Biotechnol, Intercoll Fac Biotechnol, Gdansk, Poland
[3] Med Univ Gdansk, Gdansk, Poland
[4] Med Univ Gdansk, Lab Human Physiol, Gdansk, Poland
[5] Med Univ Gdansk, Lab Cell Biol, Dept Med Biotechnol, Intercoll Fac Biotechnol UG MUG, Gdansk, Poland
[6] Med Univ Gdansk, Dept Pharmaceut Chem, Gdansk, Poland
关键词
anticancer; apoptosis; benzenesulfonamide; metabolic stability; mitochondrial membrane potential; QSAR; synthesis; CANCER; CELLS;
D O I
10.1111/cbdd.12955
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of novel 2-alkylthio-4-chloro-N-(5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives 12-46 have been synthesized by the reaction of aminoguanidines with an appropriate alpha-oxo-acids hydrates in glacial acetic acid. All the synthesized compounds were evaluated for their anticancer activity against HeLa, HCT-116, and MCF-7 human tumor cell lines. Two compounds 33 and 34 displayed outstanding cytotoxic effect selectively toward HeLa cancer cells (IC50=19m) and did not exhibit toxicity to the non-cancerous HaCaT cells. QSAR analysis determined the most important parameters controlling cytotoxic activity of 5-oxo-1,2,4-triazines against HeLa cells. QSAR model showed five significant descriptors: HATS6s (GETAWAY descriptor), RDF125m (radial distribution function), SpMax7_Bh(p) (Burden descriptor), SM3_G (3D matrix descriptor), and Hy (hydrophilic factor). The apoptotic potential of the most active compounds was thoroughly analyzed through various assays: cells' morphology, DNA fragmentation, mitochondrial potential disruption, and phosphatidylserine translocation. Selected compounds were tested for metabolic stability in the presence of pooled human liver microsomes and NADPH. Compound 34 was the most resistant for human metabolism (t(1/2)=38.5min) and can be pointed as a hit compound for further investigations.
引用
收藏
页码:380 / 396
页数:17
相关论文
共 23 条
[1]  
Bonowska J., 2016, MOLECULES, V21, P808
[2]   How not to develop a quantitative structure-activity or structure-property relationship (QSAR/QSPR) [J].
Dearden, J. C. ;
Cronin, M. T. D. ;
Kaiser, K. L. E. .
SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2009, 20 (3-4) :241-266
[3]   Promoting apoptosis as a strategy for cancer drug discovery [J].
Fesik, SW .
NATURE REVIEWS CANCER, 2005, 5 (11) :876-885
[4]   Targeting apoptosis for anticancer therapy [J].
Fulda, Simone .
SEMINARS IN CANCER BIOLOGY, 2015, 31 :84-88
[5]   Cyclocondensation reaction of heterocyclic carbonyl compounds, Part XIII: Synthesis and cytotoxic activity of some 3,7-diaryl-5-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e][1,2,4]triazines [J].
Gucky, Tomas ;
Frysova, Iveta ;
Slouka, Jan ;
Hajduch, Marian ;
Dzubak, Petr .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (02) :891-900
[6]   Synthesis and characterization of novel 1,2,4-triazine derivatives with antiproliferative activity [J].
Krauth, Fabian ;
Dahse, Hans-Martin ;
Ruettinger, Hans-Hermann ;
Frohberg, Petra .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (05) :1816-1821
[7]   FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma [J].
Lee, Hyon-Zu ;
Kwitkowski, Virginia E. ;
Del Valle, Pedro L. ;
Ricci, M. Stacey ;
Saber, Haleh ;
Habtemariam, Bahru A. ;
Bullock, Julie ;
Bloomquist, Erik ;
Shen, Yuan Li ;
Chen, Xiao-Hong ;
Brown, Janice ;
Mehrotra, Nitin ;
Dorff, Sarah ;
Charlab, Rosane ;
Kane, Robert C. ;
Kaminskas, Edvardas ;
Justice, Robert ;
Farrell, Ann T. ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2015, 21 (12) :2666-2670
[8]   DABRAFENIB IN THE TREATMENT OF ADVANCED MELANOMA [J].
Medina, T. ;
Amaria, R. N. ;
Jimeno, A. .
DRUGS OF TODAY, 2013, 49 (06) :377-385
[9]  
Negwer M., 1994, ORGANIC CHEM DRUGS T
[10]  
Nguyen Diana T, 2013, J Adv Pract Oncol, V4, P53